Joint Formulary & PAD

Dupilumab - Chronic Obstructive Pulmonary Disease (COPD)

You are here : Home > Formulary Search > Dupilumab - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
ICB
R
SPC
Restrictions / Comments :
Important

Initiation and prescribing by respiratory specialists only.

SASH--Awaiting implementation of service.

Documents :
 
NICE Technology Appraisal
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils NICE TA1142
Evidence Review
Sy Sx Dupilumab APC NICE TA Consulation Briefing paper 20260518.docx

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Dupilumab
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
02 Jun 2026
Latest Additions Date To :
31 Jul 2026
Guidelines :
Chronic Obstructive Pulmonary Disease (COPD)
Supporting Documents :
2

Committee Recommendations (1)

02 Jun 26 - Surrey & Sussex Area Prescribing Committee (APC)

The Surrey and Sussex Integrated Care Board Area Prescribing Committee supports use in line with NICE TA1142 as an add-on maintenance treatment for adults with uncontrolled COPD characterised by raised blood eosinophils, where disease remains inadequately controlled despite optimised inhaled therapy.

Other Indications

Below are listed other indications that Dupilumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).